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Background
Protein-protein interaction networks and mechanistic
pathway models are excellent tools in the drug discovery
process. They can be used to identify and select targets for
a given disease hypothesis. Combining information from
diverse sources, like in house experiments as well as liter-
ature, allows further development of interaction networks
into detailed descriptions of cellular pathways. Compu-
terized pathway diagrams allow integrating all relevant
data regarding a project into one framework by linking the
different data sources. Interaction networks analysis and
pathway design tools are used to support target identifica-
tion and validation activities. Experimental results are
incorporated in protein interaction networks, analyzed
and further developed into biomolecular pathopathways
including literature findings to understand the underlying
modulation mechanisms. The pathway diagrams are also
used as communication tools, particularly for interdisci-
plinary project teams, thus ensuring a common under-
standing and facilitating critical interrogations about
disease hypotheses. The analyses of experimental results,
the initial construction of an HD pathopathway are pre-
sented and two mechanistic disease hypotheses are dis-
cussed.
Materials and methods
Differential proteomics experiments (DPEs) were per-
formed on rat PC12 cells containing either wild-type or
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Functional classification by cellular process of the proteins co firmed to be modulated in the DPEsigu e 1
Functional classification by cellular process of the proteins 
confirmed to be modulated in the DPEs. Numeric values indi-
cate the number of proteins in each class. The results of MS 
identification using partially overlapping databanks (UniProt, 
and rat ENSEMBL+GENSCAN) were stored in a relational 
database designed in-house. Redundancy was removed and 
the lists of genes encoding the identified proteins were 
mapped on networks using MetaCore http://
www.genego.com/metacore.php for analysis. In agreement 
with the experimental design, the apoptosis process is not 
present amongst the functional classes, while the "Stress 
response & Chaperones", "Energy metabolism" and "Proteas-
ome degradation" are the best represented processes in the 
final results set.Page 1 of 3
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trol of a doxycycline-inducible promoter [1]. Cell extracts
were prepared at 0, 12, and 48 hours post-induction to
identify proteins involved in pre-apoptotic intracellular
events. Protein expression modulation was measured
using DIGE technology [2] followed by statistical analysis
for spot selection and automated spot picking. The pro-
tein content of each picked spot was analyzed by mass
spectrometry (MS).
Results
Three independent DPEs were performed and the modu-
lated proteins, confirmed in at least two experiments,
were analyzed in the context of protein networks. In a typ-
ical experiment, 121 differential spots were picked and
MS identification produced 3671 entries grouped into
359 proteins, an expected average of about 3 proteins per
spot [3]. In the end, 48 proteins were confirmed to be
modulated by the expression of PolyQ Htt, and were
Mechanistic pathopathway linking UCHL1 in HDFigure 2
Mechanistic pathopathway linking UCHL1 in HD. Literature and experimental findings are integrated to link proteins modu-
lated by the expression of PolyQ Htt with intracellular pathways. As a starting point, an HD pathway from the Panther pathway 
database http://www.pantherdb.org/ was used and subsequently enriched with proteins and events functionally involved in cel-
lular processes linked to neurodegeneration using CellDesigner http://celldesigner.org/. Inside the nucleus of HD patients, the 
mutant PolyQ Htt gene is transcribed into a messenger RNA with a potential stem secondary structure [9]. Intranuclear aggre-
gation of PolyQ Htt sequesters proteins binding to PolyQ Htt, including CBP, hence reducing the cAMP response element-
mediated transcription of the CREB-target genes [1]. UCHL1 was reported to potentiate CREB-target genes transcription by 
restoring normal proteasomal degradation of the PKA-regulatory subunit II alpha (PKA-r), PKA activity (PKA-c), and CREB 
phosphorylation, hence resulting in contextual memory retrieval [6].Page 2 of 3
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Ubiquitin-Proteasome system is a particularly important
biological process shown to be involved in neurodegener-
ation [4], the focus was put on the "Proteasome degrada-
tion" (Figure 1) class for enrichment of the mechanistic
HD pathopathway. In this class of cellular function, the
Ubiquitin Carboxyl-terminal Hydrolase isozyme L1
(UCHL1) protein was of particular interest, since it is
known to be associated with Parkinson [5], Alzheimer [6],
and was described as a genetic modifier of the age of onset
of HD [7,8]. Since modulation of UCHL1's mRNA by
PolyQ Htt was confirmed by RT-PCR (data not shown),
we linked UCHL1 into our HD pathopathway (Figure 2).
Divergent hypotheses can be elaborated for the role of
UCHL1 in HD. First, a positive role by contributing to
Ubiquitin recycling, thus maintaining normal Proteas-
ome pathway function counteracting the accumulation of
insoluble PolyQ Htt. Second, based on the recent discov-
ery that peptide sequences can modulate the toxicity of
PolyQ tracts in cis or trans [10], the transient interaction
between UCHL1 and PolyQ Htt to recycle Ubiquitin
could actually increase the toxicity of the extended PolyQ
tract of mutant Htt by initiating the first step of the forma-
tion of aggregates. The latter mechanism can be envisaged,
as UCHL1's structure can be superposed to a typical fibrill-
ogenic domain (Figure 3).
Conclusion
DPE results were used to develop an HD pathopathway
including proteins modulated by PolyQ Htt expression. In
this experimental result set, the proteins from the Ubiqui-
tin-Proteasome pathway were chosen for in depth analy-
sis, and UCHL1 was identified as a component potentially
playing opposite roles in HD.
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Common structural features of UCHL1 and of the Josephin do ain of Ataxin-3Figure 3
Common structural features of UCHL1 and of the Josephin 
domain of Ataxin-3. The Josephin domain of Ataxin-3 [11,12] 
was recently shown to initiate the aggregation of the entire 
protein independently of its PolyQ tract [13]. Using the 
DaliLite server http://www.ebi.ac.uk/DaliLite/, the superposi-
tion of UCHL1 (green, 2ETL) to the Josephin domain 
(orange, 1YZB) reveals a common core containing a large 
beta sheet surrounded by 3 superposed alpha helices.Page 3 of 3
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